Peptides & Longevity

What the FDA Peptide Compounding Review Means for Patients

See what the July 2026 FDA advisory votes and HHS draft mean for BPC-157, TB-500, Semax, and other peptides considered for 503A compounding.

Pharmacist reviewing folders on ingredient testing and safety near a batch record and a scale.

The FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptide families in July 2026 and supported adding six to the Section 503A Bulks List. HHS later released a draft enforcement policy covering those six. The votes were advisory. FDA approval, final compounding rules and whether a treatment is appropriate for you are separate decisions.

Woman reading an FDA advisory meeting handout and writing questions at her breakfast table.
FDA agenda, HHS draft appendix and published reports of the July votes. [3, 5–7]

What does the Pharmacy Compounding Advisory Committee do?

The Pharmacy Compounding Advisory Committee, or PCAC, advises the FDA on scientific, technical and medical questions involving drug compounding under Sections 503A and 503B. It recommends whether specific bulk ingredients should qualify for compounding. The recommendations go to the FDA commissioner, and the agency makes the regulatory decision.

The committee weighs the evidence for specific ingredients and proposed uses. Its independent advice is nonbinding. A favorable vote can inform later rulemaking, and a final rule can change which ingredients appear on the 503A Bulks List. FDA approval of a finished drug follows a separate review process. [1, 4, 22]

This matters if you have seen a claim that a positive vote makes a peptide approved or available to order. For a patient, the relevant questions are whether an approved option can meet the medical need, what evidence supports the proposed treatment, and whether a state-licensed pharmacy can fill an appropriate prescription. [4, 12]

Which peptides did the FDA committee review in July 2026?

PCAC considered the free base and acetate forms of seven peptide families on July 23 and 24, 2026. Six families received favorable recommendations for the 503A Bulks List. Emideltide, also known as DSIP, received an unfavorable recommendation. The table lists the conditions FDA reviewed for each family and the committee outcome.

Meeting datePeptide familyUses FDA reviewedPCAC recommendation
July 23BPC-157Ulcerative colitisFavorable
July 23KPVWound healing and inflammatory conditionsFavorable
July 23TB-500Wound healingFavorable
July 23MOTS-cObesity and osteoporosisFavorable
July 24Emideltide (DSIP)Opioid withdrawal, chronic insomnia and narcolepsyUnfavorable
July 24SemaxCerebral ischemia, migraine and trigeminal neuralgiaFavorable
July 24EpitalonInsomniaFavorable

Ulcerative colitis is chronic inflammation in the colon. Osteoporosis weakens bones and raises fracture risk. Narcolepsy can cause excessive daytime sleepiness and sudden sleep episodes. Cerebral ischemia is reduced blood flow to the brain. Trigeminal neuralgia can cause brief, severe facial nerve pain. The uses in the table are the scope of the agency’s review. Clinical benefit for those uses requires evidence. [3, 16–20]

For the July meeting, FDA said it would send written comments received by July 9 to the committee. Comments submitted later through July 22 went to FDA for consideration. The meeting docket was FDA-2025-N-6895. [3]

What did the HHS six-peptide draft propose?

The October 30, 2026 Federal Register notice announced a draft HHS policy describing when the department would exercise enforcement discretion for six peptide ingredients. The public comment period closed November 13. The draft concerns federal enforcement under specified conditions. Formal listing, FDA product approval and state pharmacy requirements each follow separate rules.

The public record reviewed on November 20, 2026, still identified the policy as a draft. It describes conditions for the exact ingredient and route, patient-specific prescriptions, quality documentation and adverse-event reporting for BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Emideltide is outside the draft’s scope. The codified 503A Bulks List does not include the six peptides. HHS says it can revisit the policy if safety or quality concerns arise. [5, 6, 8, 9, 23]

What evidence does FDA consider for the Section 503A Bulks List?

FDA uses four criteria to evaluate an ingredient for the Section 503A Bulks List. It looks at how well the substance can be identified, the safety issues associated with compounded use, the available evidence of effectiveness, and its history in compounding. The review is specific to the substance and the evidence submitted.

1. Ingredient identity and chemistry. Can the active ingredient be identified consistently, and what is known about its physical and chemical properties?

2. Safety in a compounded form. What risks are known or suspected, including risks that depend on the route or formulation?

3. Effectiveness evidence. What do human studies show for the uses evaluated, and where does evidence remain limited?

4. History of use in compounding. What documented experience exists with the ingredient in compounded preparations? [4, 10]

When may a pharmacy use a bulk ingredient under 503A?

The ingredient must meet an applicable U.S. Pharmacopeia (USP) or National Formulary (NF) monograph and the applicable USP compounding chapter. If there is no applicable monograph, the ingredient can qualify as a component of an FDA-approved drug product. When neither route applies, the ingredient needs to appear on the 503A Bulks List to qualify under the statutory list provision. The July review concerned that third route. FDA also requires an FDA-registered manufacturing establishment and a valid certificate of analysis for the bulk substance. [3, 4]

A plausible mechanism, early lab results, animal findings and patient reports can guide research. Product identity, human data, route-specific risk, and experience with the compounded preparation help answer a different question about suitability for compounding. [4, 10, 11]

Who votes on the committee’s recommendations?

The April 2026 PCAC charter calls for at least 10 voting members, including the chair. Members bring expertise in pharmacy, manufacturing, medicine and related fields. FDA may also appoint temporary voting members for specific topics or to meet quorum requirements. The July meeting had its own roster of regular and temporary members.

The 2024 renewal described 12 voting members, which explains the older number still found on FDA’s overview. The current charter includes seats for representatives of the National Association of Boards of Pharmacy and the U.S. Pharmacopeia, pharmacists and physicians with compounding expertise, and patient and public-health advocates. [1, 2, 13]

FDA’s standing roster, marked updated June 29, 2026, lists the chair as vacant. It lists Timothy D. Fensky as the pharmacy boards representative, Elizabeth Rebello for anesthesiology, and Brian Serumaga as the USP representative, with published terms through September 30, 2026. Those listings describe the June roster. The July meeting’s final roster shows which temporary specialists served on specific topics. [14, 15]

The standing roster lists Donnette D. Staas of Jazz Pharmaceuticals, vice president of regulatory strategy, as the nonvoting industry representative and Takyiah Stevenson, PharmD, as the designated federal officer. The charter allows FDA to add temporary voters when expertise or quorum requires it. [1, 14, 15]

How did PCAC vote on other peptides in December 2024?

The December 2024 votes show how the committee has handled limited evidence. It opposed placing the reviewed forms of AOD-9604, CJC-1295 and thymosin alpha-1 on the 503A Bulks List. The minutes identify lack of demonstrated effectiveness or insufficient safety and effectiveness evidence as concerns in the deliberations.

IngredientVotes in favor–againstWhat the minutes record
AOD-9604 free base and acetate0–12 in a joint voteThe committee recommended against listing both forms.
CJC-1295 free base0–13A member cited lack of evidence of effectiveness. The four other CJC-1295 forms also received unfavorable votes.
Thymosin alpha-1 free base and acetate4–17 for each formMembers cited insufficient evidence of clinical effectiveness and safety for the uses reviewed.

What safety issues can matter before you fill a prescription?

FDA’s safety materials flag peptide impurities, difficulty confirming ingredient identity, limited human exposure data, and possible immune reactions that may depend on the route. These issues vary by substance. A physician evaluates whether treatment is medically appropriate, and the dispensing pharmacy confirms that it can meet requirements for the exact preparation.

FDA’s interim Category 2 safety materials identify GHRP-2 for injectable and nasal routes, GHRP-6 and ipamorelin acetate under Section 503B, kisspeptin-10 under Section 503A, and ibutamoren mesylate under both. These designations apply to the agency’s respective interim bulk-substance policies. [11]

FDA separately discusses substances whose nominations were withdrawn, including AOD-9604, BPC-157, CJC-1295, emideltide, Epitalon, injectable GHK-Cu, KPV, MOTS-c, Semax, TB-500, and thymosin alpha-1. FDA describes concerns across these ingredients involving impurities, characterization, immune reactions or sparse human safety data. The concern for any given ingredient depends on the evidence and route. [11]

Man discussing questions about peptide approval with a physician on an illustrated Peplix Health video visit.
Illustrative telehealth visit about what a peptide review means for an individual care decision.

What are three questions you can ask a physician?

  • What diagnosis or symptom are we treating, and could an FDA-approved treatment meet my needs?
  • What human evidence supports this specific formulation and route for someone with my health history?
  • If a compound is appropriate, who will dispense it and how will we track benefits and side effects?

Common questions about PEPLIX HEALTH

Peplix Health is a cash-pay telehealth service managed by Monarch Brands LLC. An independent, board-certified physician reviews your symptoms, history and goals. When treatment is clinically appropriate, the physician tailors the prescription, dose and follow-up. A state-licensed pharmacy may fill an eligible compounded prescription under applicable federal and state requirements.

Did the July advisory vote approve BPC-157 or TB-500?

The vote was a recommendation on bulk ingredient listing. HHS later included both in its six-peptide draft. A favorable recommendation and the draft each leave FDA product approval and final 503A listing to separate processes. [3, 4, 6, 8]

Does Section 503A mean the compounded product is FDA approved?

Section 503A sets conditions for eligible compounding. Compounded drugs do not go through FDA premarket review for safety, effectiveness or quality. The physician and pharmacy each have distinct responsibilities in prescribing and dispensing. [4, 12]

Can I request a specific peptide at a Peplix Health visit?

You can ask about it and bring the name and proposed use. The physician assesses your medical need, the evidence and suitable alternatives. A consultation does not establish that any particular product is offered or can be dispensed in your state.

What should I bring to my appointment?

Bring your current medications and supplements, relevant health history, and the symptoms or goals you want to discuss. If an online claim prompted your visit, bring the exact product name and the claim so you can review it with your physician.

For consultation information, see our longevity guide or start an online assessment.

Medical information notice. This article is educational. A licensed clinician can assess the risks, benefits and alternatives for your individual situation.